Business Context and Reporting Period
This Form 8-K Current Report was filed by Xcyte Therapies, Inc. (not Bio Green Med Solution, Inc.) on June 17, 2005. The report details the approval of amendments to the company's equity compensation plans at the 2005 Annual Meeting of Stockholders.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or debt metrics. The only financial data provided relates to equity plan parameters:
- 2003 Stock Plan: Aggregate shares issuable increased to 1,345,453 (an increase of 600,000).
- Directors' Plan: Aggregate shares issuable increased to 440,909 (an increase of 350,000).
- Stock Price: The closing sale price on June 16, 2005, was $0.63 per share.
Material Changes
Stockholders approved the following material changes to equity plans:
- 2003 Stock Plan Amendments:
- Increased share pool by 600,000 shares.
- Expanded award types to include restricted stock, restricted stock units, and stock appreciation rights.
- Amended for compliance with Section 162(m) of the Internal Revenue Code.
- Directors' Plan Amendments:
- Increased share pool by 350,000 shares.
- Increased option grants for new directors (10,000 shares) and annual grants for serving directors (10,000 shares).
- Added committee chair/audit committee member grants (2,500 shares).
- Grant Activity:
- 291,353 options under the 2003 Plan were granted subject to approval, including grants to CEO Ronald Berenson (31,848 shares) and Chairman Christopher Henney (200,000 shares).
- 75,000 options were automatically granted to non-employee directors at the meeting.
Outlook, Risks, and Unusual Items
Change of Control Provisions: The filing outlines specific vesting accelerations in the event of a sale, merger, or liquidation:
- 2003 Plan: If a successor assumes awards, the lesser of 25% of initial shares or remaining unvested shares vests immediately. An additional 25% vests if the holder is "involuntarily terminated" within one year post-closing. If awards are not assumed, 100% of shares vest immediately prior to closing.
- Directors' Plan: All outstanding options accelerate, vest in full, and become fully exercisable immediately prior to the consummation of a sale or merger.
Unusual Items: The filing notes that prior to the meeting, certain options were granted but were not exercisable until stockholder approval was obtained.
Investor Verification Checklist
- Verify the total number of shares authorized under the amended 2003 Plan (1,345,453) and Directors' Plan (440,909).
- Confirm the exercise prices of recent grants ($2.29 for executives, $1.50 for Chairman, $0.63 for directors).
- Review the full text of the 2003 Plan and Directors' Plan (Exhibits 10.1 and 10.2) for detailed vesting schedules and repurchase rights.
- Assess the dilution impact of the 600,000 and 350,000 share increases relative to the current outstanding share count.